PureTech Health plc - PRTC
About Gravity Analytica
Recent News
- 09.29.2025 - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
- 09.29.2025 - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
- 09.11.2025 - PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgoTM (SPT-320) in Healthy Volunteers
- 09.11.2025 - PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgoTM (SPT-320) in Healthy Volunteers
- 08.28.2025 - PureTech to Present 2025 Half Year Results
- 08.28.2025 - PureTech to Present 2025 Half Year Results
- 08.28.2025 - PureTech Health plc – Half-Year Report
- 08.28.2025 - PureTech Health plc – Half-Year Report
- 08.21.2025 - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
- 08.21.2025 - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF